Advanced Liposomal Vectors as Cancer Vaccines in Melanoma Immunotherapy

References

• Adamina M., Bolli M., et al. Encapsulation into sterically stabilised liposomes enhances the immunogenicity of melanoma-associated Melan-A/MART-1 epitopes. Br. J. Cancer 2004; 90: 263–269, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Adamina M., Daetwiler S., et al. Clinical applications of recombinant virus-based cancer immunotherapy. Expert. Opin. Biol. Ther 2005a; 5: 1211–1224, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Adamina M., Oertli D. Antigen specific active immunotherapy: lessons from the first decade. Swiss. Med. Wkly 2005b; 135: 212–221, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Adamina M., Schumacher R., Spagnoli G. C. Liposomes in Cancer Immunotherapy. Liposome Technology 3rd, G. Gregoriadis. Taylor & Francis CRC Press, New York 2006; Volume III, in press
   Google Scholar
• Albo F., Cavazza A., et al. Degradation of the tumor antigen epitope gp100(280–288) by fibroblast-associated enzymes abolishes specific immunorecognition. Biochim. Biophys. Acta 2004; 1671: 59–69, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Amoscato A. A., Prenovitz D. A., Lotze M. T. Rapid extracellular degradation of synthetic class I peptides by human dendritic cells. J. Immunol 1998; 161: 4023–4032, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Arkema A., Huckriede A., et al. Induction of cytotoxic T lymphocyte activity by fusion-active peptide-containing virosomes. Vaccine 2000; 18: 1327–1333, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Balch C. M., Buzaid A. C., et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J. Clin. Oncol 2001; 19: 3635–3648, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Banchereau J., Palucka A. K., et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 2001; 61: 6451–6458, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Cavazza A., Adamina M., et al. Hydrolysis of the tumor-associated antigen epitope gp100(280–288) by membrane-associated and soluble enzymes expressed by immature and mature dendritic cells. Clin. Immunol 2004; 111: 252–261, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Coley W. B. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. Am. J. Med. Sci 1893; 105: 487–511, [CSA]
   Google Scholar
• Copland M. J., Baird M. A., et al. Liposomal delivery of antigen to human dendritic cells. Vaccine 2003; 21: 883–890, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Dudley M. E., Wunderlich J. R., et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298: 850–854, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Durrer P., Gluck U., et al. Mucosal antibody response induced with a nasal virosome-based influenza vaccine. Vaccine 2003; 21: 4328–4334, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Figdor C. G., de V. I., et al. Dendritic cell immunotherapy: mapping the way. Nat. Med 2004; 10: 475–480, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Gluck R., Moser C., Metcalfe I. C. Influenza virosomes as an efficient system for adjuvanted vaccine delivery. Expert. Opin. Biol. Ther 2004; 4: 1139–1145, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Hodge J. W., Grosenbach D. W., Schlom J. Vector-based delivery of tumor-associated antigens and T-cell co-stimulatory molecules in the induction of immune responses and anti-tumor immunity. Cancer Detect. Prev 2002; 26: 275–291, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Kawamura K., Kadowaki N., et al. Dendritic cells that endocytosed antigen-containing IgG-liposomes elicit effective antitumor immunity. J. Immunother 2006; 29: 165–174, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Lowe D. B., Shearer M. H., Kennedy R. C. DNA vaccines: Successes and limitations in cancer and infectious disease. J. Cell Biochem 2006; 98: 235–242, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Mocellin S., Rossi C. R., et al. Dissecting tumor responsiveness to immunotherapy: the experience of peptide-based melanoma vaccines. Biochim. Biophys. Acta 2003; 1653: 61–71, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Novellino L., Castelli C., Parmiani G. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol. Immunother 2005; 54: 187–207, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• O'Hagan D. T., Valiante N. M. Recent advances in the discovery and delivery of vaccine adjuvants. Nat. Rev. Drug Discov 2003; 2: 727–735, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Oertli D., Marti W. R., et al. Rapid induction of specific cytotoxic T lymphocytes against melanoma- associated antigens by a recombinant vaccinia virus vector expressing multiple immunodominant epitopes and costimulatory molecules in vivo. Hum. Gene Ther 2002; 13: 569–575, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Parmiani G., Castelli C., et al. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?. J. Natl. Cancer Inst 2002; 94: 805–818, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Rosenberg S. A., Yang J. C., et al. Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma. Clin. Cancer Res 2003; 9: 2973–2980, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Schneider J., Gilbert S. C., et al. Induction of CD8+ T cells using heterologous prime-boost immunisation strategies. Immunol. Rev 1999; 170: 29–38, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Schumacher R., Adamina M., et al. Influenza virosomes enhance class I restricted CTL induction through CD4+ T cell activation. Vaccine 2004; 22: 714–723, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Schumacher R., Amacker M., et al. Efficient induction of tumoricidal cytotoxic T lymphocytes by HLA-A0201 restricted, melanoma associated, L(27)Melan-A/MART-1(26–35) peptide encapsulated into virosomes in vitro. Vaccine 2005; 23: 5572–5582, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Schumacher R., Spagnoli G. C., Adamina M. Influenza virosomes as adjuvants in Cancer Immunotherapy. Liposome Technology 3rd, G. Gregoriadis. Taylor & Francis CRC Press, New York 2006; II, in press
   Google Scholar
• Schwaninger R., Waelti E., et al. Virosomes as new carrier system for cancer vaccines. Cancer Immunol. Immunother 2004; 53: 1005–1017, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Singh M., O'Hagan D. Advances in vaccine adjuvants. Nat. Biotechnol 1999; 17: 1075–1081, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Tartaglia J., Bonnet M. C., et al. Therapeutic vaccines against melanoma and colorectal cancer. Vaccine 2001; 19: 2571–2575, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Thurner B., Haendle I., et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med 1999; 190: 1669–1678, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• van der Bruggen P., Traversari C., et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 1643–1647, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Weber J., Sondak V. K., et al. Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma. Cancer 2003; 97: 186–200, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• World Health Organization. (2005). Evidence and Information for Health Policy. WHO Statistical Information System. http://www3.who.int/whosis/menu.cfm
   Google Scholar
• Zajac P., Oertli D., et al. Phase I/II clinical trial of a nonreplicative vaccinia virus expressing multiple HLA-A0201-restricted tumor-associated epitopes and costimulatory molecules in metastatic melanoma patients. Hum. Gene Ther 2003; 14: 1497–1510, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar